During the historical era from 2016 to 2020, the market for cancer profiling saw significant growth. The industry generated more than US$ 900 million in revenue in 2018, increasing at a 4% annual growth rate, claims FactMR. 2019 saw the creation of an absolute opportunity valued US$36 million.

By providing accurate and current information about the consumer’s demands, their changing tastes, attitudes, preferences, purchasing intentions, etc., market research such as that covered in this Cancer Profiling Market report aids a company’s management in planning. The brand of the product and the needs and preferences of the consumer can be correlated with the help of this study. Additionally, this study highlights important industry market dynamics. A clear understanding of the market share analysis can be gained from the report’s competitive landscape part.

The company profiles of all the major market players and brands that are dominating the Cancer Profiling with moves like product launches, joint ventures, merges, and accusations which in turn are affecting the sales, import, export, revenue, and CAGR values have been cited in the report. The study consists of a market attractiveness analysis, wherein each segment is benchmarked based on its market size, growth rate, and general attractiveness.

Cancer profiling is a type of genomic testing that involves analyzing the DNA and RNA of cancer cells to identify patterns that are associated with certain types of cancer. This type of testing is used to develop personalized cancer treatments and to monitor the progression of the disease. Cancer profiling can help doctors to identify which treatments may be most effective for a particular patient and to develop strategies to prevent cancer recurrence.

Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=358

Competitive Landscape

To maintain their market presence, the aforementioned players employ a variety of organic and inorganic growth strategies. Offering new products, developing strategic alliances, acquiring and merging with other players, and conducting clinical trials to determine drug efficacy are just a few examples.

F. Hoffmann-La Roche Ltd., for example, presented updated overall survival (OS) data from its Phase III IMbrave 150 study, which compared Tecentriq® (atezolizumab) in combination with Avastin® (bevazicumab) to sorafenib in people with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy.
Illumina Inc. announced new and expanded oncology partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck in January 2021 to advance comprehensive genomic profiling. These collaborations were formed in order to broaden the TruSightTM Oncology 500 (TSO 500) Research Use Only comprehensive pan-cancer assay’s ability to profile known and emerging biotumors.
QIAGEN NV recently announced a collaboration with INOVIO to develop next generation sequencing (NGS) companion diagnostics for the latter’s VGX-3100 cervical dysplasia treatment. The first project in this expanded collaboration is the co-development of a diagnostic test that will identify women who are most likely to benefit from clinical use of VGX-3100.

Key Market Segments Covered

Product
- Instruments
  - Immunohistochemistry (IHC) Analyzers
  - Fluorescence in-situ Hybridization (FISH) Instruments
  - PCR Instruments
  - DNA Sequencer
  - Fragment Analyzer
- Consumables
  - Reagents & Kits
  - Other Ancillary (Probes, Holders, etc.)
Indication
- Breast Cancer
- Colorectal Cancer
- Ovarian Cancer
- Melanoma
- Kidney Cancer
- Lung Cancer (including NSCLC)
- Rare Cancers
End User
- Hospitals
- Diagnostic Centers
- Cancer Research Institutes
- Others
Test
- Immunohistochemistry (IHC)
- Fluorescence in-situ Hybridization (FISH)
- Qualitative Polymerase Chain Reaction (qPCR)
- Next Generation Sequencing (NGS)
- Sanger Testing
- Fragment Analysis
Region
- North America
- Latin America
- Europe
- CIS & Russia
- Japan
- APEJ
- MEA

Key Companies Profiled

F. Hoffmann La Roche Ltd
Illumina Inc.
QIAGEN
Thermo Fisher Scientific Inc.
Abbott

Nanostring Technologies Inc.
Siemens AG
HTG Molecular Diagnostics, Inc.
Perkin Elmer Inc.

Agilent Technologies Inc.
Negenomics Laboratory Inc.

Key Market Study Findings

Non-small cell lung cancer (NSCLC) is expected to grow dramatically through 2031.
Fluorescence in-situ hybridization (FISH) instruments will sell well.
The United States will see increased growth as the population’s cancer prevalence rises.
The United Kingdom will benefit from increased biological research programmes to test diagnostic efficacy.
Strong institutional frameworks are needed to accelerate oncology research and cancer profiling expansion across Germany.

India will emerge as a heavyweight in the cancer profiling market, owing to rising prevalence as a result of an exponential population increase.

Get More insights on this:https://www.factmr.com/report/358/cancer-profiling-market

Cancer Profiling Market Is Projecting a Cagr of 5% by 2031